Please read the full announcement in PDF Attachment 2024_01_All_Regulatory_Approvals_Obtained
ORION CORPORATION PRESS RELEASE 26 JANUARY 2024 at 09.00 EET Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024Orion presented yesterday…
NEWTOWN SQUARE, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to…
SAN MATEO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing…
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group"), a clinical-stage life science biotechnology company pioneering the…
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its…
Clinical experience with investigational ARC-EX® Therapy showcased on the main stage and in clinical abstracts during the 2024 NANS Annual…
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today…
SAN RAMON, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report first quarter 2024…
Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of…